Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 17/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48143 | 0.84 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL48213 | 0.81 | SLC5A2 (0.50) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3689201 | 0.73 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL48221 | 0.72 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL13082853 | 0.71 | SLC5A2 (0.86) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13082373 | 0.71 | SLC5A2 (0.86) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10211841 | 0.69 | SLC5A2 (0.73) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10211947 | 0.69 | SLC5A2 (0.73) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12782141 | 0.68 | SLC5A2 (0.70) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16572162 | 0.68 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| WO-2009076550-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.